Panel Discussion: What’s the New Path to the Next Generation of ADCs?

• Understanding how to migrate from non-selective ADC payloads
• Debating the right properties for a next generation payload and linker: Can (or should?) any small molecule therapeutic be developed into an ADC?
• Debating the right strategy for dual-payload ADCs
• Understanding ADC toxicity and developability for next-generation conjugates

Panel Session Hosted By:

Speakers:

Bob Lutz

Chief Scientific Officer

Iksuda Therapeutics

Allan Jordan

Vice President, Oncology Drug Discovery

Sygnature Discovery

Joshua Greally

ADC Lead

Sygnature Discovery

Ya-Chi Chen

Chief Scientific Officer

OBI Pharma

Mohit Trikha

President & Chief, Operating Officer

Oncology Drug Design